Ceritinib (LDK378)

For research use only. Not for use in humans.

目录号：S7083

CAS No. 1032900-25-6

Ceritinib (LDK378)是一种有效的ALK抑制剂，在无细胞试验中IC50为0.2 nM。Ceritinib (LDK378)还可抑制IGF-1R、InsR、STK22D和FLT3对应的IC50值分别为8 nM、7 nM、23 nM和60 nM。Phase 3。

规格

价格

库存

购买数量

5mg	RMB 1182.86	现货
50mg	RMB 3868.47	现货
200mg	RMB 10720.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ceritinib (LDK378)发表文献64篇：

Nature, 2019, 10.1038/s41586-019-1472-0

PubMed: 31391581 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 39(1):151-163

PubMed: 31462708 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )
Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Biochem J, 2019, 10.1042/BCJ20190106

PubMed: 31341009 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00802-7

PubMed: 31177400 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4162-4174

PubMed: 29776956 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(6):2487-2499

PubMed: 29742496 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):73-83

PubMed: 29133622 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )
J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Cancer Sci, 2017,

PubMed: 27783866 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1118-1125

PubMed: 29045271 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 40(5):1129-1140

PubMed: 27960155 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):601-9

PubMed: 26639656 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1118-1133

PubMed: 27432227 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Oncol, 2015, 10.1016/j.molonc.2015.11.007

PubMed: 26639656 ( click the link to review the publication )

Oncotarget, 2015, 6(42):44643-59

PubMed: 26556876 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(4):566-571

PubMed: 25450694 ( click the link to review the publication )

产品安全说明书

ALK抑制剂选择性比较

生物活性

产品描述

特性

不与c-Met交叉反应，对体内葡萄糖稳态比TAE684效果好，有效作用于 Crizotinib复发的肿瘤。

靶点

ALK ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	STK22D ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)
0.2 nM	7 nM	8 nM	23 nM	60 nM

体外研究

LDK378作用于Ba/F3-NPM-ALK和Karpas290细胞，具有显著的抗增殖活性，IC50分别为26.0 nM 和 22.8 nM,作用于Ba/F3-Tel-InsR 和Ba/F3-WT细胞，IC50分别为319.5 nM 和 2477 nM。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Parental(+IL3)	NV3V[3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIHyboU4OiCq	MYTEUXNQ	NGXVd2FKSzVyPUG1PFYhyrFiMUezJI5O	NHrWbWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
WT 70	NUXlVldtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVu3NkBp	MYnEUXNQ	MVXJR\|UxRTJzINMxJFghdk1?	Mn7pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEmwN\|QoRjJ3N{S5NFM1RC:jPh?=
G1128S 1022	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHHQfJM4OiCq	MYHEUXNQ	MVzJR\|UxRTFyMjFCtUA{QCCwTR?=	NUfrVYdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFkxOzRpPkK1O\|Q6ODN2PD;hQi=>
C1156F 1293	NWnVcnp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkfGO\|IhcA>?	NUDMbHRITE2VTx?=	MX\JR\|UxRTJzNzFCtUAyOTVibl2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
I1171N 519	M2PJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIThSno4OiCq	MnLRSG1UVw>?	NIXZTJhKSzVyPUG4O{DDuSB6NzDuUS=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
I1171T 445	NYnD[XgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXPFSWl[PzJiaB?=	NVnRUppDTE2VTx?=	MX\JR\|UxRTh{INMxJFEzKG6P	M3ntclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
F1174I 184	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mm\qO\|IhcA>?	NVy2UnpXTE2VTx?=	Mn;iTWM2OD1zMzFCtUAxNjFibl2=	NWOxempzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFkxOzRpPkK1O\|Q6ODN2PD;hQi=>
N1178H 169	NULZNlgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn7zO\|IhcA>?	MnfVSG1UVw>?	MUDJR\|UxRTR{INMxJFYhdk1?	M1W0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5NFM1Lz5{NUe0PVA{PDxxYU6=
E1210K 748	M3vheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoD4O\|IhcA>?	MlHqSG1UVw>?	Ml3TTWM2OD1zOEegxtEhQDRibl2=	NIHke5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVA{PCd-MkW3OFkxOzR:L3G+
C1156F/D1203N 2809	NHnNU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTRO\|IhcA>?	M2\WOmROW09?	MYPJR\|UxRTJ3NDFCtUA6QSCwTR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUCzOEc,OjV5NEmwN\|Q9N2F-
Ba/F3 NA WT	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4LwS\|czKGh?		Ml;6TWM2OD1yLkCyNEDPxE1?	M4W1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 NA C1156Y	NXfCUGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV3Ve5dlPzJiaB?=		M1PJW2lEPTB;MD6wO\|Eh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 NA L1196M	M3vrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFXzeoQ4OiCq		NXTSUI5UUUN3ME2wMlA1OiEQvF2=	M{jlT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 NA L1152R	M1LJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXO3NkBp		NXjWcZVvUUN3ME2wMlI5QCEQvF2=	NIW0XJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 NA G1202R	MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEHZNXM4OiCq		MkfFTWM2OD1yLkK3O{DPxE1?	M2PiNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 NA G1269A	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4PhTFczKGh?		NEjvXXJKSzVyPUCuNFE6KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 NA S1206Y	M3yzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;CRoIxPzJiaB?=		NIK1OFhKSzVyPUCuNFM4KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA WT	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3[zS\|czKGh?		MonCTWM2OD1yLkCyNUDPxE1?	M4\Bb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 EA C1156Y	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlP3O\|IhcA>?		MV\JR\|UxRTBwMEK2JO69VQ>?	NVXvRYJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 EA L1196M	NX36fXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXXsendTPzJiaB?=		NH3McWNKSzVyPUCuNFE6KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{SwNEc,OjV5Mke0NFA9N2F-
Ba/F3 EA L1152R	NHHhZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVqy[plSPzJiaB?=		MkLTTWM2OD1yLkC5PUDPxE1?	NWX2bWVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
Ba/F3 EA G1202R	NHrrZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmTGO\|IhcA>?		MnXzTWM2OD1yLkS2O{DPxE1?	NIjCfXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO\|QxOCd-MkW3Nlc1ODB:L3G+
Ba/F3 EA G1269A	NGLNWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXi3NkBp		M3\2UGlEPTB;MD6wN\|Mh\|ryP	M1zJdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3OFAxLz5{NUeyO\|QxODxxYU6=
Ba/F3 EA S1206Y	NVe1NHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH;HXFY4OiCq		MoTuTWM2OD1yLkCzPEDPxE1?	NUjVRZV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3Nlc1ODBpPkK1O\|I4PDByPD;hQi=>
BAF3	NV;zO4FpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2L1UlczKGi{cx?=		NFHMWnFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDTVmIhd3JiQ1PLPEBie3OjeTygTWM2OCB;IECuNFExPyEQvF2u	NEfLfYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
NCI-H3122	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHTCbY44OiCqcoO=		NWPKdYVDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkCxOUDPxE1w	M2DGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
NCI-H2228	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2PoT\|Mh\GG7cx?=		MnXWS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh{MkK4JINmdGy\|IHHmeIVzKDNiZHH5d{BjgSCudX3pcoV{[2WwY3WtZoF{\WRiQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IECuNFE2KM7:TT6=	M2mxOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK3O\|I2Lz5{OU[yO\|czPTxxYU6=
SU-DHL1	NVXCNIk6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoXJN{Bl[Xm\|		MV;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTWU1FUExzIHPlcIx{KGGodHXyJFMh\GG7czDifUBtfW2rbnXzZ4Vv[2VvYnHz[YQhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NEA:KDBwMEG1JO69VS5?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ{N{eyOUc,Ojl4Mke3NlU9N2F-
DFCI114	NFqzOlNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFuxSZI4OiCqcoO=		MofWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGRlPJNVE1KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTzF{NknBJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNFE5KM7:TT6=	Mnz6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
HCC78	MorJR5l1d3SxeHnjbZR6KGG\|c3H5		NV\RWYUyPzJiaILz		NUT2ZWFuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOFN{igZ4VtdHNiaHHyZo9zcW6pIGPMR\|M1STJvUl;TNUBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAyQCEQvF2u	NVnT[4t1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0O\|Q6OjVpPkK3OFc1QTJ3PD;hQi=>
KARPAS299	M3z1e2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3XCb\|IhfG9iMzDkZZl{		M4fp[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCWlCDU{K5PUBk\WyuczDh[pRmeiB{IITvJFMh\GG7czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCyNlgh\|ryPLh?=	NHyzcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
KARPAS299	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=				MnLMR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2FTWEGVMkm5JINmdGy\|IHX4dJJme3OrbnegUnBONUGOSzDmeZNqd25iZ3Xu[UBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NEA:KDBwMEKyPEDPxE1w	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh\|N{e5O{c,OjN6M{e3PVc9N2F-
NCI-H3122	MoX4SpVv[3Srb36gZZN{[Xl?		M3;yZ\|czKGi{cx?=		MV;Jcohq[mm2aX;uJI9nKEWPTESg[pV{\WRiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFPDOVAhRSByLkCyOUDPxE1w	NX7hZ\|BtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVUyPjlpPkK3PVE2OTZ7PD;hQi=>
BAF3	M37tUGZ2dmO2aX;uJIF{e2G7		MmnGNkB1dyB\|IHThfZM>		Mn;STY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgNkB1dyB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xOjZizszNMi=>	NUnlWVFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BA/F3	NFP0PHZEgXSxdH;4bYNqfHliYYPzZZk>				MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKE6STT3BUGsh\nW\|aX;uJIdmdmViYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36sJGlEPTBiPTCwMlAzPiEQvF2u	NIfnUmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izO\|c6Pyd-MkO4N\|c4QTd:L3G+
KARPAS299	Ml74RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXi3NkBpenN?		NX3mNmszSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEK2JO69VS5?	M4m3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUe0PFA6Lz5{OUG3OFgxQTxxYU6=
NCI-H2228	NEPKNo1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFTET404OiCqcoO=		MkO0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMhcGG{Yn;ybY5oKEWPTEStRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB{NjFOwG0v	Mn:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
KARPAS299	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=		MX63NkBpenN?		M1;BfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCWlCDU{K5PUBk\WyuczDoZZJjd3KrbnegUnBONUGOSzDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyO{DPxE1w	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR5NEmyOUc,Ojd2N{S5NlU9N2F-
Ba/F3	MmXESpVv[3Srb36gZZN{[Xl?		Mlz6O\|IhcHK\|		MWfJcohq[mm2aX;uJI9nKEWPTEStRWxMKFNzMkC2XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODN\|IN88UU4>	NYHzNY16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
NCI-H3122	Mn7jRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				Mnz2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{NCCFQ{WwJF0hOC5yM{ig{txONg>?	MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{W5OFUoRjJ4MkO1PVQ2RC:jPh?=
NCI-H3122	M3SyU2Z2dmO2aX;uJIF{e2G7		NYjLZlUyPzJiaILz		MlvrTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhS0N3MDC9JFAvODN6IN88UU4>	NG\meZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyN\|Y6PSd-Mk[5NlM3QTV:L3G+
NCI-H3122	MVPGeY5kfGmxbjDhd5NigQ>?		MWC3NkBpenN?		MoPNTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhS0N3MDC9JFAvODN6IN88UU4>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{M{[5OUc,OjZ7MkO2PVU9N2F-
NCI-H3122	NX:4VI1jTnWwY4Tpc44h[XO\|YYm=		NETo[2Y4OiCqcoO=		NULPN3puUW6qaXLpeIlwdiCxZjDFUWw1KG[3c3XkJGFNUyCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBESzVyIE2gNE4xOzhizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN6NUWwOUc,Ojh\|OEW1NFU9N2F-
BA/F3	MYTGeY5kfGmxbjDhd5NigQ>?				MmjyTY5pcWKrdHnvckBw\iCDTFugLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyxiSVO1NEA:KDBwMESwO{DPxE1w	NIrLRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izO\|c6Pyd-MkO4N\|c4QTd:L3G+
Ba/F3	NGfaNoFHfW6ldHnvckBie3OjeR?=		MoqzO\|IhcHK\|		MlnETY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE1CVEtiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNFQyKM7:TT6=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Ba/F3	NXm2Z49kTnWwY4Tpc44h[XO\|YYm=		MUm3NkBpenN?		MYPJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0MWFNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6wOFEh\|ryPLh?=	MkTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
KARPAS299	NHvmUmVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUO3NkBpenN?		MlfaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMhcGG{Yn;ybY5oKE6STT3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODRzIN88UU4>	M3q0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
BAF3	Mn7HRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn\BO\|IhcHK\|		MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIFyxNVk3VSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4xPTR7IN88UU4>	M2TpOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Ba/F3	MXnGeY5kfGmxbjDhd5NigQ>?		MUW3NkBpenN?		NXPTSmVJUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDHNVI3QUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkC1O{DPxE1w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
HCC78	NHv2colCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlHiO\|IhcHK\|		MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{e4JINmdGy\|IHjhdoJwemmwZzDTUGM{PEF{LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODV6IN88UU4>	MojoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
HCC78	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MY[3NkBpenN?		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{e4JINmdGy\|IHjhdoJwemmwZzDTUGM{PEF{LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODV6IN88UU4>	M3;ySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
Ba/F3	MmCwSpVv[3Srb36gZZN{[Xl?		MVu3NkBpenN?		MYXJcohq[mm2aX;uJI9nKEWPTEStRWxMKExzMUm2UUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODZ2IN88UU4>	NGPHNoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
DFCI76	NHLpWlNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MV:3NkBpenN?		NF7YcoRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTGR2k4PiClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKExzMUWyVkBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlA4OiEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
BAF3	NFjSZnlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NXnNdmIzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQtKEOFNUCgQUAxNjB5NTFOwG0v	M2PtN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkO1PVQ2Lz5{NkKzOVk1PTxxYU6=
BA/F3	NVvWc5UyTnWwY4Tpc44h[XO\|YYm=		MU[3NkBpenN?		MmjiTY5pcWKrdHnvckBw\iCDTFugUFEyQT[PIH31eIFvfCCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliV2PUNUBie3OjeTygR2M2OCB;IECuNFc2KM7:TT6=	Ml[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MkO2PVUoRjJ4OUKzOlk2RC:jPh?=
BA/F3	MUfGeY5kfGmxbjDhd5NigQ>?		NGHG[mU4OiCqcoO=		Mk\GTY5pcWKrdHnvckBw\iCHTVy0JIZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygR2M2OCB;IECuNFc2KM7:TT6=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzNUG2PUc,Ojd7MUWxOlk9N2F-
BA/F3	MWfGeY5kfGmxbjDhd5NigQ>?		M4K0eFczKGi{cx?=		M4XJSmlvcGmkaYTpc44hd2ZiRV3MOEBnfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCFQ{WwJF0hOC5yN{Wg{txONg>?	M1jmcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUG1NVY6Lz5{N{mxOVE3QTxxYU6=
BAF3	M2\XRmZ2dmO2aX;uJIF{e2G7		Mk[wO\|IhcHK\|		NXLrTmFtUW6qaXLpeIlwdiCxZjDBUGshVDFzOU\NJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGfTWE0yKGG\|c3H5MEBESzVyIE2gNE4xPzVizszNMi=>	MlmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|OEW1NFUoRjJ6M{i1OVA2RC:jPh?=
KARPAS299	M2K2emFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{HZUVczKGi{cx?=		NFraVZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCqYYLic5JqdmdiTmDNMWFNUyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB6NDFOwG0v	MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
SMS-KCNR	NUezR4ZSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEDD[5o4OiCqcoO=		M3v1NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU13TMWtEVlJiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCUMUK3OXEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4xQTJizszNMi=>	Ml23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
NCI-H3122	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NITzUnQ4OiCqcoO=		NITMZ25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB7NjFOwG0v	NIrmc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
NCI-H2228	NVqxbXlMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGHhfXQ4OiCqcoO=		M174OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOUmg{txONg>?	M1nUSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUe0PFA6Lz5{OUG3OFgxQTxxYU6=
Ba/F3	MVnGeY5kfGmxbjDhd5NigQ>?		M4DibFczKGi{cx?=		M3;TNmlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiRkGxO\|RNKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC5zMEGg{txONg>?	NXXrTIxiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
NCI-H2228	Mk\2R5l1d3SxeHnjbZR6KGG\|c3H5		M3S1XlczKGi{cx?=		M1nTd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMkKyPEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6xNFI3KM7:TT6=	M2\tXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkS0OlcyLz5{NU[0OFY4OTxxYU6=
LAN5	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUS3NkBpenN?		MmiwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOQV61JINmdGy\|IHX4dJJme3OrbnegSW1NPC2DTFugVlEzPzWTIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDBwMUKyJO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
SU-DHL1	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2jLXFczKGi{cx?=		NVXlcXl6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWU1FUExzIHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOTJ{IN88UU4>	MnjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Kelly	M3O2cWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWfCc25LPzJiaILz		NVflXop7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlE1OiEQvF2u	M1PX[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Ba/F3	MYnGeY5kfGmxbjDhd5NigQ>?		MkH0O\|IhcHK\|		NV;rOIVDUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDDNVE2PllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkG2OEDPxE1w	NYjBSIg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
SH-SY5Y	NXPweWJISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVLZc5VwPzJiaILz		MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOKLWPZOXkh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BHOTF5NFygcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6xPFYh\|ryPLh?=	NHToV4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	M2PEbWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoXTO\|IhcHK\|		NXn3WHg{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BETDd2LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4zOzRizszNMi=>	NWLFOoFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
SK-N-SH	NFrUU5lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV;xfVUzPzJiaILz		NHP1VGlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uW0hiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4{ODNizszNMi=>	NGrNcZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	NGX1eVZHfW6ldHnvckBie3OjeR?=		NEj3NlMzKHSxIEOg[IF6ew>?		MV3Jcohq[mm2aX;uJI9nKFSHTD3meZNm\CCrboP1cIlvKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5\|MUm1JO69VS5?	NX7BeoE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BA/F3	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=				MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJHRmdC2LboPSJIdmdmViYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36sJGlEPTBiPTCwMlMzKM7:TT6=	MnnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{e3PVcoRjJ\|OEO3O\|k4RC:jPh?=
SK-N-FI	NIPCSHNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYm3NkBpenN?		NXrBWHZOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU[LIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6zOFkh\|ryPLh?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
CHLA20	Ml:0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmHYO\|IhcHK\|		NH;lV4dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUGEzOCClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKFJzMke1VUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlM3OyEQvF2u	NGKyNmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Ba/F3	MVXGeY5kfGmxbjDhd5NigQ>?		MVW3NkBpenN?		M{nhUGlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiR{GyNFJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC52NESg{txONg>?	M2HN[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
LAN1	M1;BVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFHKSFk4OiCqcoO=		MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyDTkGgZ4VtdHNiZYjwdoV{e2mwZzDFUWw1NUGOSzDGNVE4PExibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOC53NEmg{txONg>?	M33yT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
SK-N-BE(2)	M{nNbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3TFOlczKGi{cx?=		M332U2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1DTSh{KTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFUWw1NUGOSzDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuOVk{KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Ba/F3	M4rKVGZ2dmO2aX;uJIF{e2G7		M4fRUVczKGi{cx?=		NYiyOWl2UW6qaXLpeIlwdiCxZjDFUWw1NUGOSzCxNVUyXGmwczDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQnGvSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuOlY5KM7:TT6=	NIL3eoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
BAF3	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2q3XVczKGi{cx?=		MmnjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDFUWw1NUGOSzDHNVIxOlJibYX0ZY51KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvPzJ4IN88UU4>	NUfiSWRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Ba/F3	MlHvSpVv[3Srb36gZZN{[Xl?		NWTlboxiPzJiaILz		NI\JSnNKdmirYnn0bY9vKG:oIHj1cYFvKEWJRmKg[IVtOTlxVEe5NG0wSzd7N2OgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE44QDB3IN88UU4>	NFG2cYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGzOlQ3PSd-MkmxN\|Y1PjV:L3G+
SK-N-AS	M1XFcWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYr5N2dmPzJiaILz		MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tRXMh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhTU2OND3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAyNjB2NTFOwG0v	NYnZOXBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
BAF3	M2f1NGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NE[yUI4zKHSxIEOg[IF6ew>?		M3S3fGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgNkB1dyB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNk41PzdizszNMi=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
Ba/F3	NFrGR\|lHfW6ldHnvckBie3OjeR?=		MXG3NkBpenN?		MnL2TY5pcWKrdHnvckBw\iCHTVy0MWFNUyCOMUG1NnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAzNjd2NzFOwG0v	M3LGSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
BA/F3	MmflR5l1d3SxeHnjbZR6KGG\|c3H5		MVW3NkBpenN?		MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gOU42OTJizszNMi=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
KARPAS299	MVLBdI9xfG:\|aYOgZZN{[Xl?	NIrIVI03OCCwTR?=	Mk\GNlQhcHK\|		M4rZcmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGG2IE[wJI5OKGGodHXyJFI1KGi{czDifUBi[3KrZHnu[UBwemGwZ3Wv[ZRpcWSrdX2gZpJwdWmmZTDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgcYlkem:\|Y3;wbYMhdWW2aH;k	Ml;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
SU-DHL1	NGPuR5VHfW6ldHnvckBie3OjeR?=	MV2yNEB1dyB{MECgcm0>	M{jyOlEhcHJ?		MlTCTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHH0JHk4ODVicnXzbYR2\SCjdDCyNEB1dyB{MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NFi3O2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SU-DHL1	NWjZ[VB6TnWwY4Tpc44h[XO\|YYm=	MnuzNlAhfG9iMkCwJI5O	M3:ySlEhcHJ?		NUHDSpZ2UW6qaXLpeIlwdiCxZjDBUGsheGixc4Doc5J6dGG2aX;uJIF1KFlzMke4JJJme2mmdXWgbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjdDCyNEB1dyB{MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M1\Vc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
NCI-H3122	M4W0dGZ2dmO2aX;uJIF{e2G7	NUn0WlVWOjBidH:gNlAxKG6P	MoTvNUBpeg>?		M4rudGlvcGmkaYTpc44hd2ZiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRWLLJJBpd3OyaH;yfYxifGmxbjDheEBVOjB{Lz;ZNlA1KHKnc3nkeYV{KGG2IEKwJJRwKDJyMDDuUUBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NVX0SlJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
NCI-H3122	NVHtV5NlTnWwY4Tpc44h[XO\|YYm=	NYTrXG5kOjBidH:gNlAxKG6P	M1n3cVEhcHJ?		M1vTUGlvcGmkaYTpc44hd2ZiQVzLJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iQXv0JJBpd3OyaH;yfYxifGmxbjDheEBUPDd\|IILld4llfWViYYSgNlAhfG9iMkCwJI5OKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M2PJdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
SU-DHL1	NYP0bHZuTnWwY4Tpc44h[XO\|YYm=	NU\GbGxWOjBidH:gNlAxKG6P	MUCxJIhz		MnXyTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSWu2IIDoc5NxcG:{eXzheIlwdiCjdDDTOFc{KHKnc3nkeYUh[XRiMkCgeI8hOjByIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NFrjdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
SU-DHL1	M{DxR2Z2dmO2aX;uJIF{e2G7	NVWzTHVNOjBidH:gNlAxKG6P	MmDyNUBpeg>?		MVHJcohq[mm2aX;uJI9nKEGOSzDpckBpfW2jbjDTWU1FUExzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9vKGG2IGSyNFIwN1l{MESgdoV{cWS3ZYOgZZQhOjBidH:gNlAxKG6PIHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NU\rd5d5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
NCI-H3122	MYTGeY5kfGmxbjDhd5NigQ>?	NUT0VnB{OjBidH:gNlAxKG6P	NUXSTYt[OSCqch?=		MVHJcohq[mm2aX;uJI9nKEGOSzDwbI9{eGixconsZZRqd25iYYSgXVEzPzhicnXzbYR2\SCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[XRiMkCgeI8hOjByIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MnXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
NCI-H3122	MlvuSpVv[3Srb36gZZN{[Xl?	NUniTJJLOjBidH:gNlAxKG6P	NHrFSWgyKGi{		MnTVTY5pcWKrdHnvckBw\iCDTFugbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDy[ZNq\HWnIHH0JFIxKHSxIEKwNEBvVSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
SU-DHL1	Mn3ISpVv[3Srb36gZZN{[Xl?	M2jEW\|MxKG6P	MlfkNVYhcHK\|		MUDJcohq[mm2aX;uJI9nKEGOSzDheZRweGixc4Doc5J6dGG2aX;uJIF1KFlzNUC3JJJme2mmdXWgbY4hcHWvYX6gV3UuTEiOMTDj[YxteyCjdDCzNEBvVSCjZoTldkAyPiCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NYHBTnp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2Nlc4OjVpPkK5OlI4PzJ3PD;hQi=>
SU-DHL1	NX;3WWJ7TnWwY4Tpc44h[XO\|YYm=	NVP3R\|YxOzBibl2=	MkSxNVYhcHK\|		NFSxRoJKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBUXS2GSFyxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDy[ZNq\HWnIHH0JFMxKG6PIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	Mne2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4Mke3NlUoRjJ7NkK3O\|I2RC:jPh?=
NCI-H3122	MkTJSpVv[3Srb36gZZN{[Xl?	MVW1NEB1dyB{NUCgcm0>	NGjNVnoyPiCqcoO=		MXjJcoR2[3Srb36gc4YhSUyNIHTl[5Ji\GG2aX;uJIlvKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCDTFugdIhwe3Cqb4L5cIF1cW:wIHH0JHkyPjB2IHH0JFUxKHSxIEK1NEBvVSCjZoTldkAyPiCqcoOgZpkhcW2vdX7vZoxwfCCvZYToc4Q>	NF23N5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
SH-SY5Y	NITwUVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkTsO\|IhcHK\|		Mmf4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSD3TXVV[KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5	NETEWHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
CHLA20	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYS3NkBpenN?		Mn7lRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFSFzBNlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYm=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ4MEm4OEc,Ojl4NkC5PFQ9N2F-
SH-SY5Y	NY\QXHI3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUW3NkBpenN?		M{nxdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1itV3k2YSClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhSUKFQkGgbY5pcWKrdH;yJJRiemmzdXnkZZIh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeR?=	MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
KARPAS299	M1nJcWZ2dmO2aX;uJIF{e2G7	NFHtOow2OCC2bzCyOVAhdk1?	NIf4RXcyPiCqcoO=		MkHWTY5lfWO2aX;uJI9nKEGOSzDk[Ydz[WSjdHnvckBqdiCqdX3hckBMSVKSQWOyPVkh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iQVzLJJBpd3OyaH;yfYxifGmxbjDheEB[OTZyNDDheEA2OCC2bzCyOVAhdk1iYX\0[ZIhOTZiaILzJIJ6KGmvbYXuc4Jtd3RibXX0bI9l	NInQNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[2NFk5PCd-Mkm2OlA6QDR:L3G+
CHLA20	NFrBOnhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnKwO\|IhcHK\|		NFu2T5FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUGEzOCClZXzsd{Bi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhSUKFQkGgbY5pcWKrdH;yJJRiemmzdXnkZZIh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeR?=	NUn0SYtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OlA6QDRpPkK5OlYxQTh2PD;hQi=>
NCI-H3122	Mmm3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn7qO\|IhcHK\|		M1vQTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6	M1P0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
KARPAS299	Mo[4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2LGc\|czKGi{cx?=		MnXHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZk>	M3PNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Nk[wPVg1Lz5{OU[2NFk5PDxxYU6=
SU-DHL1	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYi3NkBpenN?		Mlm2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGwyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG\|c3H5	Ml7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NkC5PFQoRjJ7Nk[wPVg1RC:jPh?=
KARPAS299	MXLBdI9xfG:\|aYOgZZN{[Xl?	Ml7POVAhdk1?	NGjtSVczPCCqcoO=		NWDkcZJvUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgeY5kdGWjcjDj[YxtKHOqcnnub4Fo\SCjdDC1NEBvVSCjZoTldkAzPCCqcoOgZpkhUG:nY3jzeEA{OzJ3ODDzeIFqdmmwZzDiZZNm\CCrbo\ldpRm\CCobIXvdoV{[2WwY3WgcYlkem:\|Y3;wfS=>	NH\MR4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKyN\|EzOCd-M{CyNlMyOjB:L3G+
KARPAS299	MXTBdI9xfG:\|aYOgZZN{[Xl?	MnfGOVAhdk1?	MYiyOEBpenN?		MlLTTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNQWLQRXMzQTliY3XscJMh[XO\|ZYPz[YQh[XNibHH0[UBieG:ydH;0bYMh[2WubIOgZZQhPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IFHPM2VDKGSxdXLs[UB{fGGrbnnu[{Bj[XOnZDDpcpZmenSnZDDmcJVwemW\|Y3XuZ4UhdWmlcn;zZ49xgQ>?	NUTDcolpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
KARPAS299	MWnBdI9xfG:\|aYOgZZN{[Xl?	NETOOIc2OCCwTR?=	MXSyOEBpenN?		NInVOHVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCjc4Pld5Nm\CCjczDmdoFodWWwdHH0bY9vKGG2IEWwJI5OKGGodHXyJFI1KGi{czDifUBJd2WlaIP0JFM{OjV6IIP0ZYlvcW6pIHLhd4VlKGmwdnXyeIVlKG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5	NWrzR2NGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK; PubMed: 28425916 eLife Inhibition of ALK autophosphorylation and downstream signaling by ceritinib, crizotinib and PF06463922 in NB-1 cells. Cells were harvested after treatment for 4 hr with the indicated compounds at different concentrations. Whole cell lysates were analyzed by Western blotting to detect the levels of ALK, AKT and ERK proteins and their phosphorylation. pROS1 / ROS1 / pSTAT3 / STAT3 ; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.	28425916 25351743
Growth inhibition assay	Cell viability; PubMed: 29067644 Target Oncol The effects of ceritinib treatment on cell viability in ARMS and ERMS cell lines. Cells were treated with 0-5 μM ceritinib for 72 h (Rh30, RD), 120 h (Rh41), or 144 h (Rh18, Aska) and cell viability was assessed. The y-axis represents relative cell viability compared to non-treated cells (control). Effects on cell viability were determined in triplicate. Values are presented as mean ± SD. Dotted line represents the IC50-value. The human synovial sarcoma cell line Aska with constitutive ALK phosphorylation was used as a positive control.	29067644

体内研究

LDK378 用于降低形成反应代谢的可能性，在肝微粒体几乎检测不到谷胱甘肽（GSH）加合物的水平（<1％）。LDK378具有相对良好的代谢稳定性，中度抑制CYP3A4（Midazolam底物）和抑制hERG。LDK378处理动物，与肝脏血流量相比，具有低的血浆清除率（小鼠，大鼠，狗和猴），处理小鼠，大鼠，狗和猴的口服生物利用度都在55％以上。LDK378 处理Karpas299 和H2228 大鼠移植瘤模型，抑制肿瘤生长，诱导肿瘤衰退，这种作用具有剂量依赖性，体重没有降低。LDK378处理小鼠，剂量高达100 mg/kg，对胰岛素水平或血浆葡萄糖的利用无影响。^[1]

激酶实验：^[1]	- 合并激酶分析: 所有激酶使用杆状病毒表达技术表达为组氨酸或GST标签的融合蛋白，除了在大肠杆菌中产生的未标记的ERK2。在LabChip迁移实验中测量激酶活性。实验在30°C下进行60分钟。在有或无LDK378存在时，通过线性进展曲线，获得LDK378对酶活性的作用效果。
细胞实验：^[1]	- 合并 Cell lines: Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 细胞 Concentrations: ~100 μM Incubation Time: 2-3 天 Method: 表达荧光素酶的细胞与连续稀释的LDK378 或 DMSO 温育2-3天。荧光素酶的表达用来衡量细胞增殖/存活，使用Bright-Glo萤光素酶检测系统来评估。使用 XLFit软件获得 IC50值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带 Karpas299/H2228肿瘤的 RNU裸鼠 Dosages: ~50 mg/kg Administration: 口服饲喂 (Only for Reference)

参考文献

[1] Marsilje TH, et al. J Med Chem. 2013, Jun 6.

溶解度 (25°C)

体外	DMSO	20 mg/mL warmed (35.83 mM)
	Ethanol	3 mg/mL (5.37 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ceritinib (LDK378) SDF

分子量	558.14
化学式	C₂₈H₃₆ClN₅O₃S
CAS号	1032900-25-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02450903	Completed	Drug: LDK378	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	August 21 2015	Phase 2
NCT02040870	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	March 7 2014	Phase 1\|Phase 2
NCT01950481	Completed	Drug: LDK378	Normal Hepatic Function\|Impaired Hepatic Function	Novartis Pharmaceuticals\|Novartis	January 2014	Phase 1
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01685060	Completed	Drug: LDK378	Non-Small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	November 26 2012	Phase 2
NCT01634763	Completed	Drug: LDK378	Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Novartis Pharmaceuticals\|Novartis	June 2012	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to reconstitute the inhibitor for oral administration to mice?
回答：
You can resuspend LDK378 in 30% PEG400/0.5% Tween 80/5% propylene glycol and use the suspension for oral gavage feeding.

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

非特异性的ALK抑制剂

GSK1838705A : IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.
FDA批准的ALK抑制剂

Crizotinib (PF-02341066) : Approved by FDA for non-small cell lung carcinoma (NSCLC).
最新的ALK抑制剂

ASP3026 ^New : Novel and selective inhibitor for ALK with IC50 of 3.5 nM.
经典的ALK抑制剂

TAE684 (NVP-TAE684) : Potent and selective ALK inhibitor with IC50 of 3 nM, 100-fold more sensitive for ALK than InsR.

研究领域

产品类型

定制您的化合物库

Ceritinib (LDK378)

客户使用Selleck生产的Ceritinib (LDK378)发表文献64篇：

产品安全说明书

ALK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ceritinib (LDK378) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

相关ALK产品